市场调查报告书
商品编码
1380574
DNA 微阵列市场- 按产品(消耗品、仪器)、类型(互补DNA 微阵列、寡核苷酸DNA 微阵列)、应用(基因表现分析)、最终用户(学术和研究机构)、全球预测(2023年- 2032 年)DNA Microarray Market - By Product (Consumables, Instruments), Type (Complementary DNA Microarrays, Oligonucleotide DNA Microarrays), Application (Gene Expression Analysis), End-user (Academic & Research Institute), Global Forecast (2023 - 2032) |
在研发伙伴关係和策略合作激增的推动下,2023 年至 2032 年间,全球 DNA 微阵列市场的CAGR将达到 8.7%。随着业界协作努力的激增,DNA 微阵列市场规模将大幅成长。例如,2022 年 10 月,以其 DNA 定序和阵列技术的全球领先地位而闻名的 Illumina Inc. 宣布与着名的科学主导生物製药公司阿斯特捷利康 (AstraZeneca) 开展战略研究合作。
此次合作旨在利用双方在基于人工智慧 (AI) 的基因组解释和基因组分析技术方面的各自优势,并辅以丰富的行业专业知识,加速药物标靶发现。此次合作将评估利用这些技术的组合框架的潜力,以提高目标发现的效率和信心,最终根据人类组学资料的见解识别有前途的药物。这些合作伙伴关係利用集体的专业知识和资源来推动基因组研究的进步,促进创新并推动 DNA 微阵列技术在各种科学和医学应用中的采用。
整个 DNA 微阵列市场根据应用、最终用户和地区进行分类。
基因表现分析领域将在 2023 年至 2032 年间经历重大发展。随着研究人员和科学家专注于揭示基因表现模式的复杂性,对 DNA 微阵列等高通量和精确技术的需求变得至关重要。 DNA 微阵列市场需求是由对基因功能的更深入了解所推动的,有助于基因组学和个人化医疗的进步。
製药和生物技术公司细分市场从 2023 年到 2032 年将实现显着的CAGR。随着这些行业加强进行药物发现和开发的基因组研究,DNA 微阵列在高通量分析中发挥着关键作用。它们同时分析数千个基因的能力加速了研究,帮助识别潜在的药物标靶并促进精准医学和治疗干预的进步。因此,製药公司不断采用和使用证明了它们对 DNA 微阵列市场成长的贡献。
亚太地区DNA微阵列市场从2023年到2032年将呈现可观的CAGR。随着对基因组学和生命科学研究的投资不断增加,亚太地区国家对市场成长做出了重大贡献。对个人化医疗的日益关注和医疗基础设施的进步推动了 DNA 微阵列的采用,促进了该地区基因组研究的创新和科学进步。
Global DNA Microarray Market will witness 8.7% CAGR between 2023 and 2032, driven by an upsurge in partnerships and strategic collaborations for research and development. As the industry witnesses a surge in collaborative efforts, the DNA microarray market size will grow substantially. For instance, in October 2022, Illumina Inc., renowned for its global leadership in DNA sequencing and array-based technologies, revealed a strategic research collaboration with AstraZeneca, a prominent science-led biopharmaceutical company.
This partnership aims to expedite drug target discovery by leveraging their respective strengths in artificial intelligence (AI)-based genome interpretation and genomic analysis techniques, complemented by their extensive industry expertise. The collaborative effort will assess the potential of a combined framework utilizing these technologies to enhance the efficiency and confidence of target discovery, ultimately identifying promising drugs based on insights derived from human omics data. These partnerships leverage collective expertise and resources to propel advancements in genomic research, fostering innovation and driving the adoption of DNA microarray technologies in various scientific and medical applications.
The overall DNA Microarray Market is classified based on application, end-user, and region.
Gene expression analysis segment will undergo significant development from 2023 to 2032. As researchers and scientists focus on unraveling the complexities of gene expression patterns, the need for high-throughput and precise technologies like DNA microarrays becomes crucial. This DNA microarray market demand is driven by the quest for deeper insights into the functioning of genes, contributing to advancements in genomics and personalized medicine.
Pharmaceutical and biotechnology companies segment will register a noteworthy CAGR from 2023 to 2032. As these industries intensify their efforts in genomic research for drug discovery and development, DNA microarrays play a pivotal role in high-throughput analysis. Their ability to simultaneously analyze thousands of genes accelerates research, aiding in the identification of potential drug targets and facilitating advancements in precision medicine and therapeutic interventions. Therefore, the rising adoption and usage by pharmaceutical companies justifies their contribution to the DNA microarray market growth.
Asia Pacific DNA microarray market will showcase an appreciable CAGR from 2023 to 2032. With increasing investments in genomics and life sciences research, countries in the Asia Pacific contribute significantly to the market growth. The increasing focus on personalized medicine and advancements in healthcare infrastructure propel the adoption of DNA microarrays, fostering innovation and scientific progress in genomic studies within the region.